Yahoo España Búsqueda web

Entrar

Search results

  1. scholar.google.com › citations‪John F Seymour‬ - ‪Google Scholar‬

    John F Seymour. Professor of Medicine, Director Dept of Haematology Peter MacCallum Cancer Centre & Royal Melbourne. Verified email at petermac.org - Homepage. Hematologic malignancies....

  2. Imágenes

    • John F Seymour - Alchetron, The Free Social Encyclopedia
    • Photos de John Seymour - Babelio.com
    • [Police Chief John F. Seymour] — Calisphere
    • John Seymour (author) - Alchetron, The Free Social Encyclopedia
    • John Seymour (1474-1536) – kleio.org
    • John Seymour, cable-laying Master Mariner.

    Ver todo

  3. www.nejm.org › doi › fullVenetoclax–Rituximab in Relapsed or Refractory Chronic...

    22 de mar. de 2018 · Anderson MA, Deng J, Seymour JF, et al. The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism. Blood...

  4. ashpublications.org › blood › articleDegraders upgraded: the rise of PROTACs in hematological...

    28 de mar. de 2024 · John F. Seymour. Blood (2024) 143 (13): 1218–1230. https://doi.org/10.1182/blood.2023022993. Article history. Share. Tools. Abstract. Targeted protein degradation (TPD) is a revolutionary approach to targeted therapy in hematological malignancies that potentially circumvents many constraints of existing small-molecule inhibitors.

  5. ashpublications.org › blood › articleEfficacy of venetoclax plus rituximab for relapsed CLL: 5-year...

    9 de sept. de 2021 · Correspondence: John F. Seymour, Department of Haematology, Peter MacCallum Cancer Centre & Royal Melbourne Hospital, Locked Bag 1, A’Beckett St, Melbourne, VIC 3002 Australia; e-mail: john.seymour@petermac.org.

  6. pubmed.ncbi.nlm.nih.gov › 32358081Association of early disease progression and very poor ... -...

    Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression. Haematologica. 2020 May;105 (5):1465. doi: 10.3324/haematol.2020.246991.

  7. pubmed.ncbi.nlm.nih.gov › 34102145Should Undetectable Minimal Residual Disease Be the Goal of ... -...

    This review discusses available methods of minimal residual disease measurement. It summarizes minimal residual disease data from pivotal clinical trials and discusses potential implications for future studies and minimal residual disease-based clinical strategies.

  8. onlinelibrary.wiley.com › doi › 10Approach to relapsed CLL including Richter Transformation -...

    9 de jun. de 2023 · John F. Seymour. First published: 09 June 2023. https://doi.org/10.1002/hon.3146. Sections. PDF. Tools. This section will review the assessment and approved and generally available treatment options for patients with relapsed CLL, including the context of Richter Transformation (the development of diffuse large B-cell lymphoma). 1.